Previous 10 | Next 10 |
CymaBay announces trial design for RESPONSE , a global phase 3 registration stud y for seladelpar in primary biliary cholangitis (PBC) Results from the ENHANCE phase 3 study evaluating seladelpar for PBC to be featured in an oral ...
NEWARK, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced it will provide its proprietary investigational ...
NEWARK, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that a late-breaking presentation h...
Gainers: [[TRUE]] +6.2%. [[AR]] +5%. [[BCC]] +4.8%.[[GTHX]] +4.5%. [[SHLX]] +2.7%.Losers: [[ORTX]] -14.6%. [[UUU]] -6.8%. [[MDCA]] -6%. [[NRT]] -4.2%. [[CBAY]] -3%. For further details see: AR, SHLX, CBAY and ORTX among after-hours movers
NEWARK, Calif., Oct. 30, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live aud...
Gainers: [[DSS]] +26.5%. [[PRVB]] +8.4%. [[GRTS]] +4.7%. [[LILA]] +3.4%. [[NVTA]] +3.1%.Losers: [[ATHM]] -6.9%. [[MRIN]] -5.2%. [[CRMD]] -3.8%. [[QLYS]] -3.3%. [[CBAY]] -2.3%. For further details see: DSS, PRVB, ATHM and QLYS among after-hours movers
United Micro Corporation (UMC), Wipro Limited (WIT), CimbaBay Therapeutics (CBAY), Pacific Ethanol (PEIX) and Surface Oncology (SURF) are five stocks, under $10, that are rated "Strong Buys" and should continue to see gains in 2021. Plenty of tech stocks and other growth-oriented stocks ...
NEWARK, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that data from a Phase 2 study of s...
Milestone Pharmaceuticals Strengthens Board of Directors with Two New Appointments Canada NewsWire MONTREAL and CHARLOTTE, N.C., Sept. 22, 2020 MONTREAL and CHARLOTTE, N.C., Sept. 22, 2020 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST)...
Quick Take Metacrine ( MTCR ) intends to raise $85 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is developing treatment candidates for NASH conditions. MTCR is entering Phase 2 trials and will have significant capital ...
News, Short Squeeze, Breakout and More Instantly...
CymaBay Therapeutics Inc. Company Name:
CBAY Stock Symbol:
NASDAQ Market:
CymaBay Therapeutics Inc. Website:
Acquisition Reinforces Gilead’s Leadership in Developing Innovative Therapies For Challenging Liver Diseases Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for appr...
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is the focus of IBN's latest stock spotlight. The company's shares have moved 0.06% on the day to $32.49. CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chr...
2024-03-12 10:45:01 ET UiPath Inc (PATH) PATH is trading UP for the last 5 days, and it at trading at $24.64 with volume of 4,269,666 and a one day change of $0.54 (2.25%). UiPath Inc has a 52-week low of 12.38 and a 52-week high of $27.87. The business's 50-day moving average price...